You are here: Home: Audio Program Guide: CCU 2 | 2008: CCU 2 | 2008 Audio
 
  Go to Roundtable Discussion
Go to interview with David A Geller, MD
Go to interview with Eric Van Cutsem, MD, PhD
Go to interview with Robert J Mayer, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
Roundtable Discussion
Grothey, MD Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota		 Meropol, MD Neal J Meropol, MD
Director, Gastrointestinal Cancer Program; Director,
Gastrointestinal Tumor Risk Assessment Program
Divisions of Medical Science
and Population Science
Fox Chase Cancer Center
Philadelphia, Pennsylvania		 Venook, Md Alan P Venook, MD
Professor of Clinical Medicine
University of California San Francisco
San Francisco, California
           
  Click here to download the entire discussion  
Track 1 (Dr Meropol) Case discussion: A 42-year-old woman treated with adjuvant FOLFOX two years ago who now has multiple, unresectable liver metastases
Track 2 Psychosocial issues associated with a diagnosis of metastatic colorectal cancer (mCRC)
Track 3 Physician communication and patient expectations of treatment outcomes
Track 4 Therapeutic options for patients with a hepatic recurrence after adjuvant therapy
Track 5 Ongoing cooperative group trials for patients with mCRC: SWOG-80405 and ECOG-E4203
Track 6 Selecting a combination chemotherapy regimen with a biologic agent as first-line therapy for a patient with unresectable liver metastases
Track 7 Evaluation of K-ras mutations as a predictor of response to EGFR inhibitors
Track 8 PACCE trial: Analysis of K-ras mutation status and efficacy of panitumumab in patients with mCRC
Track 9 Cetuximab in the first-line metastatic setting
Track 10 Case discussion follow-up: Stable disease with FOLFIRI/bevacizumab
Track 11 (Dr Venook) Case discussion: An 80-year-old woman who underwent a right hemicolectomy for nearly obstructing colon cancer with 0/11 positive lymph nodes
Track 12 Counseling patients about adjuvant therapy
audio
Track 13 Number of lymph nodes assessed and risk of recurrence
audio
Track 14 Implications of tumor biology for making decisions about adjuvant therapy for borderline high-risk
Stage II colon cancer
audio
Track 15 Selecting patients with Stage II colon cancer for treatment with adjuvant chemotherapy
audio
Track 16 (Dr Grothey) Case discussion: A 76-year-old man with nearly obstructing CRC, multiple hepatic metastases and poor performance status
audio
Track 17 Case discussion follow-up: Dramatic response to FOLFOX/bevacizumab
audio
Track 18 (Dr Venook) Case discussion: A 42-year-old woman with rapidly progressive metastatic colon cancer who was treated with FOLFOX
audio
Track 19 Impact of children on a parent’s acceptance of modest treatment benefits
audio
     
Geller, MD David A Geller, MD
Richard L Simmons Professor of
Surgery; Co-Director
UPMC Liver Cancer Center
University of Pittsburgh
Starzl Transplant Institute
Pittsburgh, Pennsylvania

  
  Click here to download the entire interview  
Track 1 Historical perspective on surgical resection of liver-only metastases
Track 2 Specialty surgical training and outcomes from resection of liver metastases
Track 3 Therapeutic approach for patients with a synchronous primary tumor and liver metastases
Track 4 Diminished or absent role of hepatic arterial infusion in an era of newer-generation systemic therapies
Track 5 Surgical considerations for patients treated with bevacizumab
Track 6 Influence of the number of hepatic metastases on resectability
Track 7 Novel treatment approaches for liver metastases
Track 8 Surgeon’s perspective on the efficacy and tolerability of newer chemotherapy regimens in CRC
     
Cutsem, MD Eric Van Cutsem, MD, PhD
Professor of Medicine
University Hospital Gasthuisberg
Leuven, Belgium
 
  Click here to download the entire interview  
Track 1 Preoperative evaluation of patients with liver-only metastases
Track 2 EORTC-40983: Perioperative FOLFOX4 and surgery versus surgery alone for resectable liver metastases from CRC
Track 3 Clinical use of preoperative chemotherapy for patients with resectable liver metastases
Track 4 Pre- and postoperative versus postoperative-only chemotherapy for patients with resectable liver metastases
Track 5 Integrating biologic agents into neoadjuvant or adjuvant therapy
Track 6 Imaging studies for patients treated with biologic agents
Track 7 K-ras mutation status and benefit from EGFR inhibitors
Track 8 Revised eligibility criteria for trials evaluating EGFR inhibitors
Track 9 Relative efficacy of panitumumab and cetuximab
Track 10 Efficacy of bevacizumab in combination with FOLFOX as first-line therapy
Track 11 Continuation of bevacizumab upon disease progression
Audio
Track 12 Predictors of response or resistance to bevacizumab
Audio
Track 13 Adjuvant trials of bevacizumab
Audio
Track 14 Neoadjuvant bevacizumab for patients with initially unresectable liver metastases
Audio
Track 15 Clinical use of FOLFOX/cetuximab/bevacizumab
Audio
Track 16 PACCE: Chemotherapy/bevacizumab with or without panitumumab as first-line therapy for mCRC
Audio
Track 17 Potential adjuvant trial of FOLFOX in combination with bevacizumab and cetuximab
Audio
Track 18 Neoadjuvant trial of bevacizumab in rectal cancer
Audio
     
Mayer, MD Robert J Mayer, MD
Director, Center for Gastrointestinal Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
Stephen B Kay Family
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Recent advances and future directions in the management of CRC
Track 2 CALGB-C89803: Microsatellite instability predicts benefit from adjuvant irinotecan
Track 3 Influence of diet and exercise on colon cancer recurrence
Track 4 K-ras mutations and efficacy of EGFR inhibitors
Track 5 Gene assays to predict benefit from adjuvant therapy
Track 6 PACCE: First-line therapy with chemotherapy/bevacizumab with or without panitumumab in mCRC
Track 7 Observation or delayed initiation of palliative therapy for patients with mCRC
Track 8 Combination versus sequential therapy for patients with mCRC
Track 9 Duration of watchful waiting for patients with mCRC
Track 10 Use of “drug holidays” in the management of mCRC
audio
Track 11 Transitioning to hospice care
audio
Track 12 Clinical use of CT scans in the follow-up of patients with CRC
audio
Track 13 Clinical use of neoadjuvant therapy for patients with resectable liver metastases